FAAH Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

FAAH (Fatty-acid amide hydrolase) is an enzyme and a member of the serine hydrolase family. It is also an integral membrane hydrolase with a single N-terminal transmembrane domain. FAAH is responsible for the degradation of fatty acid amides, including the endocannabinoid anandamide, and for regulating palmitoylethanolamide with anti-inflammatory and analgesic properties. FAAH inhibitors selectively inhibit FAAH by displaying analgesic, anti-inflammatory, anxiolytic, and anti-depressive effects without causing any disruptions in motility, cognition, or body temperature. FAAH inhibitors are in the clinical investigative phases for post-traumatic stress disorders, anxiety disorders, pervasive child development disorders, and others. Jazz Pharmaceuticals, J&J, Autobahn Therapeutics, Astellas Pharma, BMS, Sanofi, Eisai, and Merck (MSD) are major players in the FAAH inhibitors market.

Key Market Developments:

  • In May 2021, Autobahn Therapeutics acquired ASP 3652, FAAH inhibitor from Astellas Pharma.
  • In Dec 2021, Jazz Pharmaceuticals JZP 150, a FAAH inhibitor received Fast Track designation for post-traumatic stress disorders in the USA.

Drugs under the Pipeline for FAAH Inhibitors:

  • JZP150
  • JNJ-42165279
  • ASP3652
  • ASP8477
  • CC-97489
  • SSR411298
  • V158866
  • BIA 10 2474
  • IW-6118
  • URB597

Clinical Activity and Developments of Fatty-acid amide hydrolase (FAAH) Inhibitors:

Currently, there are 10 drug products in the FAAH inhibitors, and all of them are in the clinical development phases.

  • In Dec 2021, Jazz Pharmaceuticals initiated enrolment in a phase-II trial for post-traumatic stress disorders in the USA, for JZP 150, a FAAH inhibitor.
  • In Oct 2022, Janssen Research & Development completed a phase-II trial in pervasive child development disorders in the USA for JNJ 42165279, a FAAH inhibitor.

Molecule Name

Number of Studies

JZP150

13

JNJ-42165279

9

ASP3652

8

ASP8477

2

CC-97489

2

SSR411298

2

V158866

2

BIA 10 2474

1

IW-6118

1

URB597

1

Target Indication Analysis of FAAH Inhibitors

FAAH inhibitors are in clinical development phases for mental conditions such as post-traumatic stress disorders, anxiety disorders, pervasive child development disorders, neurological disorders, cancer pain, CNS disorders, inflammation, alcoholism, neuropathic pain, and others.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Frequently Asked Questions

JZP150, JNJ-42165279, ASP3652, ASP8477, CC-97489, and SSR411298 are some of the drugs under the pipeline for FAAH inhibitors.

Jazz Pharmaceuticals, J&J, Autobahn Therapeutics, Astellas Pharma, BMS, Sanofi, Eisai, and Merck (MSD) are some of the major players in the FAAH inhibitors market.

Major indications for FAAH inhibitors are post-traumatic stress disorders, anxiety disorders, pervasive child development disorders, neurological disorders, cancer pain, and CNS disorders.

There are a total of ten molecules in the clinical development phases for FAAH inhibitors.

  • Jazz Pharmaceuticals
  • J&J
  • Autobahn Therapeutics
  • Astellas Pharma
  • BMS
  • Sanofi
  • Eisai
  • Merck (MSD)

Adjacent Markets